CHABLIS Study

The CHABLIS study compares the addition of angiotensin receptor blocker (ARB) versus an increase in ACE inhibitor dosage in patients with systolic chronic heart failure currently receiving low to medium dose ACE inhibitor.  Although ARBs have been found to be useful in heart failure it is not established whether this utility is merely on the basis of increasing renin angiotensin system blockade which can also be achieved by an increase in ACE inhibitor dose.  Therefore these two strategies have been compared head-to-head in CHABLIS with the end-point of brain natriuretic peptide being used to assess efficacy of these strategies. 

The study has now recruited approximately 100 patients and will be presented at the Cardiac Society of Australia and New Zealand meeting in 2007.